DataVXJournal of Nanoparticle ResearchPaper
journal article·2025-02

Stimuli-responsive nanoparticles: a novel approach for melanoma treatment

Biswajit Rout, Sandeep Kr Maharana, Aakanchha Jain

Journal of Nanoparticle Research· Volume 27· Issue 2
Publisher page
Bibliographic record

Abstract

No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.

Source: Not provided · Quality: missing

Research context

Nanomaterials

OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · Gold and Silver Nanoparticles Synthesis and Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (100+)

Show source-provided references
1. Natarelli N, Aleman SJ, Mark IM, Tran JT, Kwak S, Botto E, Aflatooni S, Diaz MJ, Lipner SR (2024) A review of current and pipeline drugs for treatment of melanoma. Pharmaceuticals 17:214. https://doi.org/10.3390/ph1702021410.3390/ph17020214 ↗
2. Uong A, Zon LI (2010) Melanocytes in development and cancer. J Cell Physiol 222:38–41. https://doi.org/10.1002/jcp.2193510.1002/jcp.21935 ↗
3. International Agency For Research On Cancer, Globocan (2022). https://gco.iarc.who.int/media/globocan/factsheets/cancers/16-melanoma-of-skin-fact-sheet.pdf Accessed 30 May 2024
4. International Agency For Research On Cancer, Cancer Tomorrow, (n.d.). https://gco.iarc.fr/tomorrow/en/dataviz/bubbles?populations=900&years=2035&cancers=16&types=0 Accessed 23 Jul 2024
5. International Agency For Research On Cancer, Cancer Tomorrow, (n.d.). https://gco.iarc.fr/tomorrow/en/dataviz/bubbles?populations=900&years=2035&cancers=16&types=1 Accessed 23 Jul 2024
6. Carr S, Smith C, Wernberg J (2020) Epidemiology and risk factors of melanoma. Surg Clin North Am 100(1):1–12. https://doi.org/10.1016/j.suc.2019.09.00510.1016/j.suc.2019.09.005 ↗
7. Gosman LM, Țăpoi D-A, Costache M (2023) Cutaneous melanoma: a review of multifactorial pathogenesis, immunohistochemistry, and emerging biomarkers for early detection and management. Int J Mol Sci 24:15881. https://doi.org/10.3390/ijms24211588110.3390/ijms242115881 ↗
8. Scatena C, Murtas D, Tomei S (2021) Cutaneous melanoma classification: the importance of high-throughput genomic technologies. Front Oncol 11:635488. https://doi.org/10.3389/fonc.2021.63548810.3389/fonc.2021.635488 ↗
9. Singh P, Kim HJ, Schwartz RA (2016) Superficial spreading melanoma: an analysis of 97 702 cases using the SEER database. Melanoma Res 26(4):395–400. https://doi.org/10.1097/CMR.000000000000024510.1097/CMR.0000000000000245 ↗
10. Kallini JR, Jain SK, Khachemoune A (2013) Lentigo maligna: review of salient characteristics and management. Am J Clin Dermatol 14:473–480. https://doi.org/10.1007/s40257-013-0044-610.1007/s40257-013-0044-6 ↗
11. Saidi B, Fallahi B, Fard-Esfahani A, Emami-Ardekani A, Eftekhari M (2022) Non-cutaneous melanoma, findings and prognostic value of FDG PET/CT: a case series of 23 patients and review of the literature. Asia Ocean J Nucl Med Biol 10:91–99. https://doi.org/10.22038/AOJNMB.2022.61517.143310.22038/AOJNMB.2022.61517.1433 ↗
12. Lopes J, Rodrigues CMP, Gaspar MM, Reis CP (2022) Melanoma management: from epidemiology to treatment and latest advances. Cancers (Basel) 14:4652. https://doi.org/10.3390/cancers1419465210.3390/cancers14194652 ↗
13. Curran S, Vantangoli MM, Boekelheide K, Morgan JR (2015) Architecture of chimeric spheroids controls drug transport. Cancer Microenviron 8:101–109. https://doi.org/10.1007/s12307-015-0171-010.1007/s12307-015-0171-0 ↗
14. Nurgali K, Jagoe RT, Abalo R (2018) Editorial: Adverse effects of cancer chemotherapy: anything new to improve tolerance and reduce sequelae? Front Pharmacol 9:245. https://doi.org/10.3389/fphar.2018.0024510.3389/fphar.2018.00245 ↗
15. Joyce KM (2017) Surgical management of melanoma. Exon Publ10.15586/codon.cutaneousmelanoma.2017.ch7 ↗
16. Zeng L, Gowda BHJ, Ahmed MG, Abourehab MAS, Chen Z-S, Zhang C, Li J, Kesharwani P (2023) Advancements in nanoparticle-based treatment approaches for skin cancer therapy. Mol Cancer 22:1010.1186/s12943-022-01708-4 ↗
17. Majeed H, Gupta V (2020) Adverse effects of radiation therapy10.1201/9781003000358-27 ↗
18. Verma V, Sprave T, Haque W, Simone CB, Chang JY, Welsh JW, Thomas CRJ (2018) A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors. J Immunother Cancer 6:1–15. https://doi.org/10.1186/s40425-018-0442-710.1186/s40425-018-0442-7 ↗
19. Pham JP, Joshua AM, da Silva IP, Dummer R, Goldinger SM (2023) Chemotherapy in cutaneous melanoma: is there still a role? Curr Oncol Rep 25:609–621. https://doi.org/10.1007/s11912-023-01385-610.1007/s11912-023-01385-6 ↗
20. Khan NH, Mir M, Qian L, Baloch M, Ali Khan MF, ur Rehman A, Ngowi EE, Wu DD, Ji XY (2022) Skin cancer biology and barriers to treatment: recent applications of polymeric micro/nanostructures. J Adv Res 36:223–247. https://doi.org/10.1016/j.jare.2021.06.01410.1016/j.jare.2021.06.014 ↗
21. Dang Y, Guan J (2020) Nanoparticle-based drug delivery systems for cancer therapy. Smart Mater Med 1:10–19. https://doi.org/10.1016/j.smaim.2020.04.00110.1016/j.smaim.2020.04.001 ↗
22. Rizvi SAA, Saleh AM (2018) Applications of nanoparticle systems in drug delivery technology. Saudi Pharm J SPJ Off Publ Saudi Pharm Soc 26:64–70. https://doi.org/10.1016/j.jsps.2017.10.01210.1016/j.jsps.2017.10.012 ↗
23. Allen TM, Cullis PR (2004) Drug delivery systems: entering the mainstream. Science 303(5665):1818–1822. https://doi.org/10.1126/science.109583310.1126/science.1095833 ↗
24. Emerich DF, Thanos CG (2006) The pinpoint promise of nanoparticle-based drug delivery and molecular diagnosis. Biomol Eng 23(4):171–184. https://doi.org/10.1016/j.bioeng.2006.05.02610.1016/j.bioeng.2006.05.026 ↗
25. Gelperina S, Kisich K, Iseman MD, Heifets L (2005) The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. Am J Respir Crit Care Med 172:1487–1490. https://doi.org/10.1164/rccm.200504-613PP10.1164/rccm.200504-613PP ↗
26. Yao Y, Zhou Y, Liu L, Xu Y, Chen Q, Wang Y, Wu S, Deng Y, Zhang J, Shao A (2020) Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance. Front Mol Biosci 7:193. https://doi.org/10.3389/fmolb.2020.0019310.3389/fmolb.2020.00193 ↗
27. Gavas S, Quazi S, Karpiński TM (2021) Nanoparticles for cancer therapy: current progress and challenges. Nanoscale Res Lett 16(1):173. https://doi.org/10.1186/s11671-021-03628-610.1186/s11671-021-03628-6 ↗
28. Kahraman E, Güngör S, Özsoy Y (2017) Potential enhancement and targeting strategies of polymeric and lipid-based nanocarriers in dermal drug delivery. Ther Deliv 8(11):967–985. https://doi.org/10.4155/tde-2017-007510.4155/tde-2017-0075 ↗
29. Fleige E, Quadir MA, Haag R (2012) Stimuli-responsive polymeric nanocarriers for the controlled transport of active compounds: concepts and applications. Adv Drug Deliv Rev 64:866–884. https://doi.org/10.1016/j.addr.2012.01.02010.1016/j.addr.2012.01.020 ↗
30. Subhan MA, Yalamarty SSK, Filipczak N, Parveen F, Torchilin VP (2021) Recent advances in tumor targeting via EPR effect for cancer treatment. J Pers Med 11:571. https://doi.org/10.3390/jpm1106057110.3390/jpm11060571 ↗
31. Jia R, Teng L, Gao L, Su T, Fu L, Qiu Z, Bi Y (2021) Advances in multiple stimuli-responsive drug-delivery systems for cancer therapy. Int J Nanomed 16:1525–1551. https://doi.org/10.2147/IJN.S29342710.2147/IJN.S293427 ↗
32. Pham SH, Choi Y, Choi J (2020) Stimuli-responsive nanomaterials for application in antitumor therapy and drug delivery. Pharmaceutics 12:630. https://doi.org/10.3390/pharmaceutics1207063010.3390/pharmaceutics12070630 ↗
33. Lee BK, Yun YH, Park K (2015) Smart nanoparticles for drug delivery: boundaries and opportunities. Chem Eng Sci 125:158–164. https://doi.org/10.1016/j.ces.2014.06.04210.1016/j.ces.2014.06.042 ↗
34. Gullotti E, Yeo Y (2009) Extracellularly activated nanocarriers: a new paradigm of tumor targeted drug delivery. Mol Pharm 6(4):1041–1051. https://doi.org/10.1021/mp900090z10.1021/mp900090z ↗
35. Ji T, Zhao Y, Ding Y, Nie G (2013) Using functional nanomaterials to target and regulate the tumor microenvironment: diagnostic and therapeutic applications. Adv Mater 25(26):3508–3525. https://doi.org/10.1002/adma.20130029910.1002/adma.201300299 ↗
36. Du JZ, Mao CQ, Yuan YY, Yang XZ, Wang J (2014) Tumor extracellular acidity-activated nanoparticles as drug delivery systems for enhanced cancer therapy. Biotechnol Adv 32(4):789–803. https://doi.org/10.1016/j.biotechadv.2013.08.00210.1016/j.biotechadv.2013.08.002 ↗
37. Webb BA, Chimenti M, Jacobson MP, Barber DL (2011) Dysregulated pH: a perfect storm for cancer progression. Nat Rev Cancer 11(9):671–677. https://doi.org/10.1038/nrc311010.1038/nrc3110 ↗
38. Brown JM, Wilson WR (2004) Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 4(6):437–447. https://doi.org/10.1038/nrc136710.1038/nrc1367 ↗
39. de la Rica R, Aili D, Stevens MM (2012) Enzyme-responsive nanoparticles for drug release and diagnostics. Adv Drug Deliv Rev 64(11):967–978. https://doi.org/10.1016/j.addr.2012.01.00210.1016/j.addr.2012.01.002 ↗
40. Mohapatra A, Uthaman S, Park I-K (2021) External and internal stimuli-responsive metallic nanotherapeutics for enhanced anticancer therapy. Front Mol Biosci 7:597634 (https://www.frontiersin.org/articles/10.3389/fmolb.2020.597634)10.3389/fmolb.2020.597634 ↗
41. Chang D, Ma Y, Xu X, Xie J, Ju S (2021) Stimuli-responsive polymeric nanoplatforms for cancer therapy. Front Bioeng Biotechnol 9:1. https://doi.org/10.3389/fbioe.2021.70731910.3389/fbioe.2021.707319 ↗
42. Li Y, Lu W, Huang Q, Huang M, Li C, Chen W (2010) Copper sulfide nanoparticles for photothermal ablation of tumor cells. Nanomedicine (Lond) 5:1161–1171. https://doi.org/10.2217/nnm.10.8510.2217/nnm.10.85 ↗
43. Li Y, Ertas YN, Jafari A, Taheri M, Pilehvar Y (2023) Co-delivery of curcumin and chrysin through pH-sensitive hyaluronan-modified hollow mesoporous silica nanoparticles for enhanced synergistic anticancer efficiency against thyroid cancer cells. J Drug Deliv Sci Technol 87:104787. https://doi.org/10.1016/j.jddst.2023.10478710.1016/j.jddst.2023.104787 ↗
44. Vivek R, Nipun Babu V, Thangam R, Subramanian KS, Kannan S (2013) PH-responsive drug delivery of chitosan nanoparticles as Tamoxifen carriers for effective anti-tumor activity in breast cancer cells. Colloids Surfaces B Biointerfaces 111:117–123. https://doi.org/10.1016/j.colsurfb.2013.05.01810.1016/j.colsurfb.2013.05.018 ↗
45. Ibrahim B, Mady OY, Tambuwala MM, Haggag YA (2022) PH-sensitive nanoparticles containing 5-fluorouracil and leucovorin as an improved anti-cancer option for colon cancer. Nanomedicine 17(6):367–381. https://doi.org/10.2217/nnm-2021-042310.2217/nnm-2021-0423 ↗
46. Saroj S, Rajput SJ (2019) Facile development, characterization, and evaluation of novel bicalutamide loaded pH-sensitive mesoporous silica nanoparticles for enhanced prostate cancer therapy. Drug Dev Ind Pharm 45(4):532–547. https://doi.org/10.1080/03639045.2018.156246310.1080/03639045.2018.1562463 ↗
47. Guo F, Wu J, Wu W, Huang D, Yan Q, Yang Q, Gao Y, Yang G (2018) PEGylated self-assembled enzyme-responsive nanoparticles for effective targeted therapy against lung tumors. J Nanobiotechnol 16:1–13. https://doi.org/10.1186/s12951-018-0384-810.1186/s12951-018-0384-8 ↗
48. Zhang C, Pan D, Luo K, She W, Guo C, Yang Y, Gu Z (2014) Peptide dendrimer-doxorubicin conjugate-based nanoparticles as an enzyme-responsive drug delivery system for cancer therapy. Adv Healthc Mater 3(8):1299–1308. https://doi.org/10.1002/adhm.20130060110.1002/adhm.201300601 ↗
49. Vaghasiya K, Ray E, Sharma A, Katare OP, Verma RK (2020) Matrix metalloproteinase-responsive mesoporous silica nanoparticles cloaked with cleavable protein for “self-actuating” on-demand controlled drug delivery for cancer therapy. ACS Appl Bio Mater 3(8):4987–4999. https://doi.org/10.1021/acsabm.0c0049710.1021/acsabm.0c00497 ↗
50. Li N, Wang Z, Zhang Y, Zhang K, Xie J, Liu Y, Li W, Feng N (2018) Curcumin-loaded redox-responsive mesoporous silica nanoparticles for targeted breast cancer therapy. Artif Cells, Nanomed Biotechnol 46(sup2):921–935. https://doi.org/10.1080/21691401.2018.147341210.1080/21691401.2018.1473412 ↗
51. Li S, Saw PE, Lin C, Nie Y, Tao W, Farokhzad OC, Zhang L, Xu X (2020) Redox-responsive polyprodrug nanoparticles for targeted siRNA delivery and synergistic liver cancer therapy. Biomaterials 234:119760. https://doi.org/10.1016/j.biomaterials.2020.11976010.1016/j.biomaterials.2020.119760 ↗
52. Gupta A, Sood A, Dhiman A, Shrimali N, Singhmar R, Guchhait P, Agrawal G (2022) Redox responsive poly(allylamine)/eudragit S-100 nanoparticles for dual drug delivery in colorectal cancer. Biomater Adv 143:213184. https://doi.org/10.1016/j.bioadv.2022.21318410.1016/j.bioadv.2022.213184 ↗
53. Meng Q, Meng J, Ran W, Wang J, Zhai Y, Zhang P, Li Y (2018) Light-activated core-shell nanoparticles for spatiotemporally specific treatment of metastatic triple-negative breast cancer. ACS Nano 12(3):2789–2802. https://doi.org/10.1021/acsnano.7b0921010.1021/acsnano.7b09210 ↗
54. Mahlert L, Anderski J, Schoppa T, Mulac D, Sun J, Kuckling D, Langer K (2019) In vitro evaluation of innovative light-responsive nanoparticles for controlled drug release in intestinal PDT. Int J Pharm 565:199–208. https://doi.org/10.1016/j.ijpharm.2019.04.07710.1016/j.ijpharm.2019.04.077 ↗
55. Güleryüz B, Ünal U, Gülsoy M (2021) Near infrared light activated upconversion nanoparticles (UCNP) based photodynamic therapy of prostate cancers: an in vitro study. Photodiagnosis Photodyn Ther 36:102616. https://doi.org/10.1016/j.pdpdt.2021.10261610.1016/j.pdpdt.2021.102616 ↗
56. Zhang Q, Wang W, Shen H, Tao H, Wu Y, Ma L, Yang G, Chang R, Wang J, Zhang H, Wang C, Zhang F, Qi J, Mi C (2021) Low-intensity focused ultrasound-augmented multifunctional nanoparticles for integrating ultrasound imaging and synergistic therapy of metastatic breast cancer. Nanoscale Res Lett 16(1):73. https://doi.org/10.1186/s11671-021-03532-z10.1186/s11671-021-03532-z ↗
57. Snipstad S, Berg S, Mørch Ý, Bjørkøy A, Sulheim E, Hansen R, Grimstad I, van Wamel A, Maaland AF, Torp SH, Davies CDL (2017) Ultrasound improves the delivery and therapeutic effect of nanoparticle-stabilized microbubbles in breast cancer xenografts. Ultrasound Med Biol 43(11):2651–2669. https://doi.org/10.1016/j.ultrasmedbio.2017.06.02910.1016/j.ultrasmedbio.2017.06.029 ↗
58. Eggen S, Fagerland SM, Mørch Ý, Hansen R, Søvik K, Berg S, Furu H, Bøhn AD, Lilledahl MB, Angelsen A, Angelsen B, De Lange Davies C (2014) Ultrasound-enhanced drug delivery in prostate cancer xenografts by nanoparticles stabilizing microbubbles. J Control Release 187:39–49. https://doi.org/10.1016/j.jconrel.2014.05.02010.1016/j.jconrel.2014.05.020 ↗
59. Dalmina M, Pittella F, Sierra JA, Souza GRR, Silva AH, Pasa AA, Creczynski-Pasa TB (2019) Magnetically responsive hybrid nanoparticles for in vitro siRNA delivery to breast cancer cells. Mater Sci Eng C 99:1182–1190. https://doi.org/10.1016/j.msec.2019.02.02610.1016/j.msec.2019.02.026 ↗
60. Hayashi K, Ono K, Suzuki H, Sawada M, Moriya M, Sakamoto W, Yogo T (2010) High-frequency, magnetic-field-responsive drug release from magnetic nanoparticle/organic hybrid based on hyperthermic effect. ACS Appl Mater Interfaces 2(7):1903–1911. https://doi.org/10.1021/am100237p10.1021/am100237p ↗
61. de Escalona MM, Sáez-Fernández E, Prados JC, Melguizo C, Arias JL (2016) Magnetic solid lipid nanoparticles in hyperthermia against colon cancer. Int J Pharm 504(1–2):11–19. https://doi.org/10.1016/j.ijpharm.2016.03.00510.1016/j.ijpharm.2016.03.005 ↗
62. Yuan Z, Que Z, Cheng S, Zhuo R, Li F (2012) pH-triggered blooming of ‘nano-flowers’ for tumor intracellular drug delivery. Chem Commun 48(65):8129–8131. https://doi.org/10.1039/c2cc34225a10.1039/c2cc34225a ↗
63. Lee ES, Gao Z, Bae YH (2008) Recent progress in tumor pH targeting nanotechnology. J Control Release 132(3):164–170. https://doi.org/10.1016/j.jconrel.2008.05.00310.1016/j.jconrel.2008.05.003 ↗
64. Zhou K, Wang Y, Huang X, Luby-Phelps K, Sumer BD, Gao J (2011) Tunable, ultrasensitive pH-responsive nanoparticles targeting specific endocytic organelles in living cells. Angew Chemie - Int Ed 50(27):6109–6114. https://doi.org/10.1002/anie.20110088410.1002/anie.201100884 ↗
65. Andreev OA, Engelman DM, Reshetnyak YK (2014) Targeting diseased tissues by pHLIP insertion at low cell surface pH. Front Physiol 5:97. https://doi.org/10.3389/fphys.2014.0009710.3389/fphys.2014.00097 ↗
66. Zeng Z, Wei Z, Ma L, Xu Y, Xing Z, Niu H, Wang H, Huang W (2017) PH-responsive nanoparticles based on ibuprofen prodrug as drug carriers for inhibition of primary tumor growth and metastasis. J Mater Chem B 5(33):6860–6868. https://doi.org/10.1039/c7tb01288h10.1039/c7tb01288h ↗
67. Guan X, Hu X, Liu S, Huang Y, Jing X, Xie Z (2014) Cyclic RGD targeting nanoparticles with pH sensitive polymer–drug conjugates for effective treatment of melanoma. RSC Adv 4:55187–55194. https://doi.org/10.1039/C4RA08537J10.1039/C4RA08537J ↗
68. Mu M, Liang X, Chuan D, Zhao S, Yu W, Fan R, Tong A, Zhao N, Han B, Guo G (2021) Chitosan coated pH-responsive metal-polyphenol delivery platform for melanoma chemotherapy. Carbohydr Polym 264:118000. https://doi.org/10.1016/j.carbpol.2021.11800010.1016/j.carbpol.2021.118000 ↗
69. Sahu P, Kashaw SK, Sau S, Kushwah V, Jain S, Agrawal RK, Iyer AK (2019) pH responsive 5-fluorouracil loaded biocompatible nanogels for topical chemotherapy of aggressive melanoma. Colloids Surf B Biointerfaces 174:232–245. https://doi.org/10.1016/j.colsurfb.2018.11.01810.1016/j.colsurfb.2018.11.018 ↗
70. Sahu P, Kashaw SK, Kushwah V, Sau S, Jain S, Iyer AK (2017) pH responsive biodegradable nanogels for sustained release of bleomycin. Bioorganic Med Chem 25(17):4595–4613. https://doi.org/10.1016/j.bmc.2017.06.03810.1016/j.bmc.2017.06.038 ↗
71. Arfin S, Jha NK, Jha SK, Kesari KK, Ruokolainen J, Roychoudhury S, Rathi B, Kumar D (2021) Oxidative stress in cancer cell metabolism. Antioxidants 10(5):642. https://doi.org/10.3390/antiox1005064210.3390/antiox10050642 ↗
72. Kennedy L, Sandhu JK, Harper M-E, Cuperlovic-Culf M (2020) Role of glutathione in cancer: from mechanisms to therapies. Biomolecules 10:1429. https://doi.org/10.3390/biom1010142910.3390/biom10101429 ↗
73. Zhang Y, Xing Y, Xian M, Shuang S, Dong C (2019) Folate-targeting and bovine serum albumin-gated mesoporous silica nanoparticles as a redox-responsive carrier for epirubicin release. New J Chem 43:2694–2701. https://doi.org/10.1039/C8NJ05476B10.1039/C8NJ05476B ↗
74. Abed HF, Abuwatfa WH, Husseini GA (2022) Redox-responsive drug delivery systems: a chemical perspective. Nanomaterials 12:318310.3390/nano12183183 ↗
75. Chibh S, Kour A, Yadav N, Kumar P, Yadav P, Chauhan VS, Panda JJ (2020) Redox-responsive dipeptide nanostructures toward targeted cancer therapy. ACS Omega 5:3365–337510.1021/acsomega.9b03547 ↗
76. Khan AR, Liu Y, Yang H, Yang X, Liu S, Ji J, Zhai G (2020) Chondroitin sulfate-based redox-responsive nanoparticles for melanoma-targeted drug delivery. J Drug Deliv Sci Technol 60:102033. https://doi.org/10.1016/j.jddst.2020.10203310.1016/j.jddst.2020.102033 ↗
77. Xia J, Du Y, Huang L, Chaurasiya B, Tu J, Webster TJ, Sun C (2018) Redox-responsive micelles from disulfide bond-bridged hyaluronic acid-tocopherol succinate for the treatment of melanoma. Nanomed Nanotechnol Biol Med 14:713–723. https://doi.org/10.1016/j.nano.2017.12.01710.1016/j.nano.2017.12.017 ↗
78. Niu B, Zhou Y, Liao K, Wen T, Lao S, Quan G, Pan X, Wu C (2022) “Pincer movement”: reversing cisplatin resistance based on simultaneous glutathione depletion and glutathione S-transferases inhibition by redox-responsive degradable organosilica hybrid nanoparticles. Acta Pharm Sin B 12:2074–2088. https://doi.org/10.1016/j.apsb.2021.10.01310.1016/j.apsb.2021.10.013 ↗
79. Zhang C, Shi G, Zhang J, Niu J, Huang P, Wang Z, Wang Y, Wang W, Li C, Kong D (2017) Redox-and light-responsive alginate nanoparticles as effective drug carriers for combinational anticancer therapy. Nanoscale 9:3304–331410.1039/C7NR00005G ↗
80. Xie Y-Q, Arik H, Wei L, Zheng Y, Suh H, Irvine DJ, Tang L (2019) Redox-responsive interleukin-2 nanogel specifically and safely promotes the proliferation and memory precursor differentiation of tumor-reactive T-cells. Biomater Sci 7:1345–135710.1039/C8BM01556B ↗
81. Liu M, Du H, Khan AR, Ji J, Yu A, Zhai G (2018) Redox/enzyme sensitive chondroitin sulfate-based self-assembled nanoparticles loading docetaxel for the inhibition of metastasis and growth of melanoma. Carbohydr Polym 184:82–93. https://doi.org/10.1016/j.carbpol.2017.12.04710.1016/j.carbpol.2017.12.047 ↗
82. Bernacki RJ, Niedbala MJ, Korytnyk W (1985) Glycosidases in cancer and invasion. Cancer Metastasis Rev 4:81–101. https://doi.org/10.1007/BF0004773810.1007/BF00047738 ↗
83. Ruvolo PP (2019) Role of protein phosphatases in the cancer microenvironment. Biochim Biophys Acta - Mol Cell Res 1866:144–152. https://doi.org/10.1016/j.bbamcr.2018.07.00610.1016/j.bbamcr.2018.07.006 ↗
84. López-Otín C, Matrisian LM (2007) Emerging roles of proteases in tumour suppression. Nat Rev Cancer 7:800–808. https://doi.org/10.1038/nrc222810.1038/nrc2228 ↗
85. Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2(3):161–174. https://doi.org/10.1038/nrc74510.1038/nrc745 ↗
86. Abe T, Sakamoto K, Kamohara H, Hirano YI, Kuwahara N, Ogawa M (1997) Group II phospholipase A2 is increased in peritoneal and pleural effusions in patients with various types of cancer. Int J Cancer https://doi.org/10.1002/(SICI)1097-0215(19970620)74:3<245::AID-IJC2>3.0.CO;2-Z.10.1002/(SICI)1097-0215(19970620)74:3<245::AID-IJC2>3.0.CO;2-Z ↗
87. Kaushik N, Borkar SB, Nandanwar SK, Panda PK, Choi EH, Kaushik NK (2022) Nanocarrier cancer therapeutics with functional stimuli-responsive mechanisms. J Nanobiotechnol 20:152. https://doi.org/10.1186/s12951-022-01364-210.1186/s12951-022-01364-2 ↗
88. Li M, Zhao G, Su WK, Shuai Q (2020) Enzyme-responsive nanoparticles for anti-tumor drug delivery. Front Chem 8:647. https://doi.org/10.3389/fchem.2020.0064710.3389/fchem.2020.00647 ↗
89. Zhou Q, Shao S, Wang J, Xu C, Xiang J, Piao Y, Zhou Z, Yu Q, Tang J, Liu X, Gan Z, Mo R, Gu Z, Shen Y (2019) Enzyme-activatable polymer–drug conjugate augments tumour penetration and treatment efficacy. Nat Nanotechnol 14(8):799–809. https://doi.org/10.1038/s41565-019-0485-z10.1038/s41565-019-0485-z ↗
90. Kim JH, Moon MJ, Kim DY, Heo SH, Jeong YY (2018) Hyaluronic acid-based nanomaterials for cancer therapy. Polymers (Basel) 10:1133. https://doi.org/10.3390/polym1010113310.3390/polym10101133 ↗
91. Liu H, Yang F, Chen W, Gong T, Zhou Y, Dai X, Leung W, Xu C (2021) Enzyme-responsive materials as carriers for improving photodynamic therapy. Front Chem 9:763057. https://doi.org/10.3389/fchem.2021.76305710.3389/fchem.2021.763057 ↗
92. Mi Y, Wolfram J, Mu C, Liu X, Blanco E, Shen H, Ferrari M (2016) Enzyme-responsive multistage vector for drug delivery to tumor tissue. Pharmacol Res 113:92–99. https://doi.org/10.1016/j.phrs.2016.08.02410.1016/j.phrs.2016.08.024 ↗
93. Ruan S, Cao X, Cun X, Hu G, Zhou Y, Zhang Y, Lu L, He Q, Gao H (2015) Matrix metalloproteinase-sensitive size-shrinkable nanoparticles for deep tumor penetration and pH triggered doxorubicin release. Biomaterials 60:100–11010.1016/j.biomaterials.2015.05.006 ↗
94. Huang Y, Shi Y, Wang Q, Qi T, Fu X, Gu Z, Zhang Y, Zhai G, Zhao X, Sun Q, Lin G (2019) Enzyme responsiveness enhances the specificity and effectiveness of nanoparticles for the treatment of B16F10 melanoma. J Control Release 316:208–222. https://doi.org/10.1016/j.jconrel.2019.10.05210.1016/j.jconrel.2019.10.052 ↗
95. Yoo J-O, Ha K-S (2012) Chapter four - New insights into the mechanisms for photodynamic therapy-induced cancer cell death, in: K.W.B.T.-I.R. of C. and M.B. Jeon (Ed.), Academic Press https://doi.org/10.1016/B978-0-12-394306-4.00010-1.10.1016/B978-0-12-394306-4.00010-1 ↗
96. Zhang X, Wang S, Cheng G, Yu P, Chang J (2022) Light-responsive nanomaterials for cancer therapy. Engineering 10:18–30. https://doi.org/10.1016/j.eng.2021.07.02310.1016/j.eng.2021.07.023 ↗
97. Ruskowitz ER, Deforest CA (2018) Photoresponsive biomaterials for targeted drug delivery and 4D cell culture. Nat Rev Mater 3(2):1–17. https://doi.org/10.1038/natrevmats.2017.8710.1038/natrevmats.2017.87 ↗
98. Shibu ES, Hamada M, Murase N, Biju V (2013) Nanomaterials formulations for photothermal and photodynamic therapy of cancer. J Photochem Photobiol C Photochem Rev 15:53–72. https://doi.org/10.1016/j.jphotochemrev.2012.09.00410.1016/j.jphotochemrev.2012.09.004 ↗
99. Mura S, Nicolas J, Couvreur P (2013) Stimuli-responsive nanocarriers for drug delivery. Nat Mater 12(11):991–1003. https://doi.org/10.1038/nmat377610.1038/nmat3776 ↗
100. Linsley CS, Wu BM (2017) Recent advances in light-responsive on-demand drug-delivery systems. Ther Deliv 8:89–107. https://doi.org/10.4155/tde-2016-006010.4155/tde-2016-0060 ↗